Sep 8, 2026 06:00AM
Jul 15, 2026 08:03AM
Jul 15, 2026 08:00AM
Jun 30, 2026 08:01AM
Jun 30, 2026 08:00AM
Jun 8, 2026 08:00AM
Jun 8, 2026 08:00AM MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment
May 26, 2026 07:00PM
Apr 27, 2026 07:00PM
Mar 16, 2026 07:00AM
Jan 29, 2026 06:01PM
Jan 29, 2026 06:00PM
Jan 6, 2026 09:00AM
Dec 18, 2025 06:01AM MediciNova completes patient enrollment for neuropathy prevention study
Dec 18, 2025 06:00AM
Dec 8, 2025 06:00AM
Dec 8, 2025 06:00AM
Nov 18, 2025 06:01AM
Nov 18, 2025 06:00AM
Nov 6, 2025 06:00PM
Nov 4, 2025 07:00AM MediciNova Announces Completion of Patient Enrollment in MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
Oct 30, 2025 07:00PM
Oct 6, 2025 08:00AM
Sep 22, 2025 08:03AM
Sep 22, 2025 08:00AM
Sep 16, 2025 08:00AM
Sep 8, 2025 09:02AM
Sep 8, 2025 09:00AM MediciNova Provides Shareholder Update on Key Developments
Sep 3, 2025 07:00AM
Aug 26, 2025 07:00PM
Jul 31, 2025 07:31PM
Jul 31, 2025 07:30PM
Jul 24, 2025 06:01AM
Jul 24, 2025 06:00AM
Apr 14, 2025 07:00PM MediciNova To Participate in D. Boral’s Capital Global Conference on May 14, 2025
Apr 8, 2025 07:00PM
Dec 5, 2024 06:00PM
Nov 19, 2024 09:02AM
Nov 19, 2024 09:00AM
Nov 14, 2024 06:00PM
Nov 11, 2024 06:00PM
Oct 23, 2024 07:00PM MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium)
Sep 30, 2024 09:00AM
Sep 9, 2024 07:00PM
Sep 3, 2024 07:00PM
Aug 29, 2024 07:00PM
Jun 20, 2024 06:00AM
Jun 5, 2024 06:00AM
Jun 5, 2024 06:00AM MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer
Jun 3, 2024 06:00AM

330,739 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All